Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Steven Deitelzweig, Christine L. Baker, Amol D. Dhamane, Jack Mardekian, Oluwaseyi Dina, Lisa Rosenblatt, Cristina Russ, Tayla Poretta, Melissa Lingohr-Smith & Jay Lin. (2020) Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. Journal of Drug Assessment 9:1, pages 87-96.
Read now
Read now
Bimal R. Shah, Eva Scholtus, Catherine Rolland, Ariane Batscheider, Jason N. Katz & Kent R. Nilsson$suffix/text()$suffix/text(). (2019) A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. Current Medical Research and Opinion 35:1, pages 127-139.
Read now
Read now
A. John Camm & Keith A. A. Fox. (2018) Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion 34:11, pages 1945-1957.
Read now
Read now
Alpesh Amin, Allison Keshishian, Lien Vo, Qisu Zhang, Oluwaseyi Dina, Chad Patel, Kevin Odell & Jeffrey Trocio. (2018) Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Journal of Medical Economics 21:3, pages 244-253.
Read now
Read now
Adrienne M. Gilligan, Jessica Franchino-Elder, Xue Song, Cheng Wang, Caroline Henriques, Amy Sainski-Nguyen, Kathleen Wilson, David M. Smith & Stephen Sander. (2018) Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. Current Medical Research and Opinion 34:2, pages 285-295.
Read now
Read now
Erika L Hellenbart, Kathleen D Faulkenberg & Shannon W Finks. (2017) Evaluation of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management 13, pages 325-342.
Read now
Read now
Steven Deitelzweig, W. Richey Neuman, Melissa Lingohr-Smith, Brandy Menges & Jay Lin. (2017) Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. Journal of Medical Economics 20:12, pages 1217-1223.
Read now
Read now
Steven Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Melissa Lingohr-Smith, Brandy Menges & Jay Lin. (2017) Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion 33:10, pages 1745-1754.
Read now
Read now
Jay Lin, Jeffrey Trocio, Kiran Gupta, Jack Mardekian, Melissa Lingohr-Smith, Brandy Menges, Min You & Anagha Nadkarni. (2017) Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. Journal of Medical Economics 20:9, pages 952-961.
Read now
Read now
Articles from other publishers (27)
Prachi Arora, Maria Muehrcke, Molly Russell & Rasitha Jayasekare. (2022) Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants. Journal of Comparative Effectiveness Research 11:15, pages 1105-1120.
Crossref
Crossref
Benjamin J. R. Buckley, Deirdre A. Lane, Peter Calvert, Juqian Zhang, David Gent, C. Daniel Mullins, Paul Dorian, Shun Kohsaka, Stefan H. Hohnloser & Gregory Y. H. Lip. (2022) Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:13, pages 3788.
Crossref
Crossref
Louis Ehwerhemuepha, Kimberly Carlson, Ryan Moog, Ben Bondurant, Cheryl Akridge, Tatiana Moreno, Gary Gasperino & William Feaster. (2022) Cerner real-world data (CRWD) - A de-identified multicenter electronic health records database. Data in Brief, pages 108120.
Crossref
Crossref
Zhiyan Liu, Lingyue Ma, Hanxu Zhang, Guangyan Mu, Qiufen Xie, Shuang Zhou, Zining Wang, Zhe Wang, Kun Hu, Yanjun Gong, Jie Jiang, Qian Xiang & Yimin Cui. (2021) Comparison of non‐vitamin K antagonist oral anticoagulants on bleeding and thrombosis. Journal of Clinical Pharmacy and Therapeutics 46:6, pages 1729-1742.
Crossref
Crossref
Mirjam Hempenius, Rolf H. H. Groenwold, Patrick C. Souverein, Anthonius Boer, Olaf H. Klungel & Helga Gardarsdottir. (2021) Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology 87:9, pages 3508-3517.
Crossref
Crossref
Junguo Zhang, Xiaojie Wang, Xintong Liu, Torben B. Larsen, Daniel M. Witt, Zebing Ye, Lehana Thabane, Guowei Li & Gregory Y. H. Lip. (2021) Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. European Journal of Epidemiology 36:8, pages 793-812.
Crossref
Crossref
Alpesh AminAllison KeshishianJeffrey TrocioOluwaseyi DinaHannah LeLisa RosenblattXianchen LiuJack MardekianQisu ZhangOnur BaserAnagha NadkarniLien Vo. (2020) A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy 26:5, pages 639-651.
Crossref
Crossref
M. Jansson, S. Själander, V. Sjögren, H. Renlund, B. Norrving & A. Själander. (2020) Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation. Thrombosis Research 185, pages 135-141.
Crossref
Crossref
Antonios Douros, Madeleine Durand, Carla M. Doyle, Sarah Yoon, Pauline Reynier & Kristian B. Filion. (2019) Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety 42:10, pages 1135-1148.
Crossref
Crossref
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk & M. A. Osadchuk. (2019) Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?. Russian Journal of Cardiology:1, pages 94-102.
Crossref
Crossref
Mukul Bhattarai, Tamer Hudali, Robert Robinson, Mohammad Al-Akchar, Carrie Vogler & Youssef Chami. (2019) Impact of oral anticoagulants on 30-day readmission: a study from a single academic centre. BMJ Evidence-Based Medicine 24:1, pages 10-14.
Crossref
Crossref
Guowei Li, Gregory Y. H. Lip, Anne Holbrook, Yaping Chang, Torben B. Larsen, Xin Sun, Jie Tang, Lawrence Mbuagbaw, Daniel M. Witt, Mark Crowther, Lehana Thabane & Mitchell A. H. Levine. (2018) Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. European Journal of Epidemiology 34:2, pages 173-190.
Crossref
Crossref
Christine L. Baker, Amol D. Dhamane, Jigar Rajpura, Jack Mardekian, Oluwaseyi Dina, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith & Jay Lin. (2019) Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961987024.
Crossref
Crossref
Christine L. Baker, Amol D. Dhamane, Jack Mardekian, Oluwaseyi Dina, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith, Brandy Menges, Jay Lin & Anagha Nadkarni. (2018) Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Advances in Therapy 36:1, pages 162-174.
Crossref
Crossref
Steven Deitelzweig, Jennifer D. Guo, Patrick Hlavacek, Jay Lin, Gail Wygant, Lisa Rosenblatt, Anu Gupta, Xianying Pan, Jack Mardekian, Melissa Lingohr-Smith, Brandy Menges, Alexander Marshall & Anagha Nadkarni. (2018) Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis 24:9_suppl, pages 261S-268S.
Crossref
Crossref
Sreeram Ramagopalan, Victoria Allan, Stefania Saragoni, Luca Degli Esposti, Davide Alessandrini, Valentina Perrone, Stefano Buda, Gillian Stynes, Caterina Toma & Francesco DeSolda. (2018) Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. Journal of Comparative Effectiveness Research 7:11, pages 1063-1071.
Crossref
Crossref
Kiran GuptaJeffrey TrocioAllison KeshishianQisu ZhangOluwaseyi DinaJack MardekianLisa RosenblattXianchen LiuShalini HedeAnagha NadkarniTom Shank. (2018) Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. Journal of Managed Care & Specialty Pharmacy 24:11, pages 1116-1127.
Crossref
Crossref
Mahesh K. Vidula, Cian P. McCarthy, Neel M. Butala, Kevin F. Kennedy, Jason H. Wasfy, Robert W. Yeh & Eric A. Secemsky. (2018) Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLOS ONE 13:10, pages e0205457.
Crossref
Crossref
Alpesh AminAllison KeshishianJeffrey TrocioOluwaseyi DinaHannah LeLisa RosenblattXianchen LiuJack MardekianQisu ZhangOnur BaserAnagha NadkarniLien Vo. (2018) A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy 24:9, pages 911-920.
Crossref
Crossref
Ahmad S. Hersi, Yahya S. Alhebaishi, Omar Hamoui, Taher Hassan, Adel Khalifa Hamad, Mohamed Magdy, Hani Sabbour & Sameh Shaheen. (2018) Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa. Journal of the Saudi Heart Association 30:2, pages 122-139.
Crossref
Crossref
Ying Bai, Xu-Bo Shi, Chang-Sheng Ma & Gregory Y.H. Lip. (2017) Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. The American Journal of Cardiology 120:9, pages 1689-1695.
Crossref
Crossref
David A. Schwartz, Anthony Wang, Burak Ozbay, Martha Skup, Samantha F. Eichner, Jay Lin & Jingdong Chao. (2017) Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohnʼs Disease Treated with Biologics with or Without Previous Seton Placement. Inflammatory Bowel Diseases 23:10, pages 1860-1866.
Crossref
Crossref
Gboyega AdeboyejeGosia SylwestrzakJohn J. BarronJeff WhiteAlan RosenbergJacob AbarcaGeoffrey CrawfordRita Redberg. (2017) Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy 23:9, pages 968-978.
Crossref
Crossref
Boyoung Joung. (2017) Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. Korean Circulation Journal 47:6, pages 833.
Crossref
Crossref
Todd C. Villines & W. Frank Peacock. (2016) Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies. The American Journal of Medicine 129:11, pages S41-S46.
Crossref
Crossref
Todd C. Villines & W. Frank Peacock. (2016) Safety of direct oral anticoagulants: insights from postmarketing studies. The American Journal of Emergency Medicine 34:11, pages 9-13.
Crossref
Crossref
Marek Jauß, Sibylle Kaiser & Christian Tanislav. (2016) Neue Einsichten durch Real-World-Daten zu oralen Non-Vitamin-K-Antikoagulanzien. InFo Neurologie & Psychiatrie 18:6, pages 46-60.
Crossref
Crossref